|
Author Archive: AZBio
Regenesis Biomedical Announces Initiation of a Clinical Trial on Subjects with Painful Diabetic Distal Symmetric Peripheral Neuropathy (DSPN)
Regenesis Biomedical, a Scottsdale-based medical device company, has initiated a multi-center, randomized clinical trial assessing the Provant® Therapy System for relieving symptoms of painful diabetic distal symmetric peripheral neuropathy (DSPN).Continue reading
Operating on brain gliomas by detecting the ‘glow’
Research by Barrow Neurological Institute physicians and University of Washington scientists on novel imaging technology for malignant brain tumors was published in the April issue of World Neurosurgery.Continue reading
World-renowned heart surgeon joins Banner Health
Banner Health has announced Francisco Arabia, MD, an internationally recognized surgeon and executive leader in thoracic, cardiothoracic vascular and transplant surgery, has joined the organization.Continue reading
TGen develops quality-control test for detecting cancer in blood
Rapid, non-invasive diagnosis assisted by TGen assay could be used to help detect many types of cancerContinue reading
ASU-UA-TGEN Startup Iluminos Licenses Treatment for Alzheimer’s Disease
Iluminos Therapeutics has licensed new compounds designed to treat neurodegenerative diseases, particularly Alzheimer’s. Travis Dunckley, PhD, Assistant Research Professor at the ASU-Banner Neurodegenerative Disease Research Center helped develop the new therapies with lead inventor, Christopher Hulme, PhD, Professor of Medicinal Chemistry in the UA Department of Pharmacy and Toxicology (formerly at Eli Lilly and Amgen) and Arthur Shaw, post-doctoral research fellow at the time. The compounds were designed and synthesized at the University of Arizona (UA) College of Pharmacy, in collaboration with the Translational Genomics Research Institute (TGEN).Continue reading
Unlocking cancer’s secrets using the ‘social networks’ of cells
Megha Padi, Ph.D., of the UA Cancer Center has developed a method for probing the genetic underpinnings of cancer and other diseases, which could lead to better treatments
Built for speed: DNA nanomachines take a (rapid) step forward
Through a process known as strand displacement, a tiny walking device composed of DNA moves across a surface in a cartwheeling motion. The new device performed this feat more rapidly than any DNA walker designed to date.Continue reading
INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial
Company’s pharmaceutical-grade cannabidiol (CBD) oral solution will be evaluated by UC San Diego/CMCR researchers as potential treatment for symptoms of autismContinue reading
LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced, on May 7, 2018, that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing agreement for the LipimetiX platform of peptides (AEM-28 and analogs) for development of these drug candidates in commercial indications in mainland China, Taiwan and Hong Kong. Anji Pharma’s mission is to license and develop promising therapeutic technologies that address under-served markets in China. LipimetiX is approximately 60%-owned by Capstone Therapeutics Corp. (OTCQB:CAPS).Continue reading